文献速递神经肿瘤

高场强术中MRI与胶质瘤手术:首批100例连续患者的结果

High-field intraoperative MRI and glioma surgery: results after the first 100 consecutive patients.
PubMed 文献 · Acta Neurochir (Wien) · 2019-05-09

这项前瞻性单中心研究纳入2014年7月至2017年4月连续100例成人胶质瘤患者,在全身麻醉无术中刺激下使用高场强术中MRI(IoMRI)联合神经导航手术。结果显示中位切除程度(EOR)为100%(IQR 93.6-100),非增强肿瘤组首次IoMRI残留更高且追加切除频率为增强组的5.7倍,但第二次IoMRI后两组无差异。中位KPS在出院及术后3、6、12个月均为90,低级别与高级别胶质瘤间无统计学差异(p=0.34)。

要点

  • IoMRI联合神经导航可使胶质瘤中位EOR达100%,不受肿瘤类型或位置影响。
  • 非/轻微强化肿瘤首次IoMRI残留更高,追加切除频率为强化肿瘤的5.7倍(OR=5.7,CI 1.9-17)。
  • 仅岛叶区域残留更高(p=0.004),中位KPS在各随访点均为90。

核心结论

  • IoMRI神经导航手术无论胶质瘤类型和位置均提供最大EOR。
  • IoMRI对非或轻微强化肿瘤尤为有用。
  • 逐步切除引入「分期体积」手术概念,确保手术安全性和低永久并发症。

研究设计与样本

  • 前瞻性单中心研究,纳入2014年7月至2017年4月连续100例成人胶质瘤患者。
  • 所有患者在全麻无术中刺激下接受IoMRI联合神经导航手术。
  • 体积评估基于钆增强后FLAIR高信号(非强化肿瘤)或T1高信号(强化肿瘤)。

主要发现

  • 首次IoMRI时FLAIR组中位肿瘤残留高于T1G+组,第二次IoMRI后两组无差异(p=0.56)。
  • FLAIR组追加切除频率为T1G+组的5.7倍(OR=5.7,CI 1.9-17)。
  • 中位EOR为100%(IQR 93.6-100),无论肿瘤类型(初发或复发)和位置。
  • 仅岛叶区域残留更高(p=0.004)。

关键数值与推荐

  • 中位EOR为100%(IQR 93.6-100)。
  • FLAIR组追加切除OR=5.7(CI 1.9-17)。
  • 第二次IoMRI后两组残留差异p=0.56。
  • 岛叶区域残留更高p=0.004。
  • 中位KPS为90(IQR 80-100)在出院及术后3、6、12个月,低级别与高级别胶质瘤间p=0.34。

临床怎么用

  • 对胶质瘤患者采用IoMRI联合神经导航手术以最大化EOR。
  • 对非或轻微强化肿瘤应更积极使用IoMRI并考虑追加切除。
  • 岛叶区域肿瘤需注意残留风险,可考虑多次IoMRI控制。
  • 逐步切除策略(「分期体积」手术)有助于保障手术安全性和低永久并发症。

局限性

  • 单中心前瞻性研究,样本量100例。
  • 未报告随机对照或盲法设计。
  • 未报告长期随访结局(如无进展生存期或总生存期)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-field intraoperative MRI (IoMRI) is part of the neurosurgical armamentarium to improve the extent of glioma resection (EOR). OBJECTIVE: To report our oncological and functional outcomes using IoMRI for neuronavigated glioma surgery. METHODS: In this prospective monocentric study, we reported 100 consecutive adult patients operated on for glioma using IoMRI with neuronavigation, under general anesthesia without intraoperative stimulation, from July 2014 to April 2017. The volumetric evaluation was based on the FLAIR hypersignal for non-enhancing tumors after Gadolinium infusion and on the T1 hypersignal after Gadolinium infusion for enhancing tumors. We evaluated the surgical workflow, the EOR and the clinical outcomes (using Karnofsky performance score (KPS)). RESULTS: Sixty-nine patients underwent one IoMRI, and 31 from two IoMRI controls. At first IoMRI, the median tumor residue was higher in the FLAIR group than in the T1G+ group whereas no more difference was reported after the second IoMRI between the 2 groups (p = 0.56). Additional resection was performed 6 times more frequently in the FLAIR group (OR = 5.7, CI (1.9-17)). The median EOR was 100% (IQR, 93.6-100) whatever the tumor type (first surgery or recurrence) and location. Higher residues were reported only in the insula area (p = 0.004). The median KPS was 90 (IQR, 80-100) at discharge, 3, 6 and 12 months after surgery, with no statistical difference between low- and high-grade gliomas (p = 0.34). CONCLUSION: IoMRI neuronavigated surgery provided maximal EOR whatever the type of glioma and location. IoMRI was all the more useful for non- or minimally enhancing tumors. The step by step surgical resection, introducing the concept of "staged volume" surgery, ensured a high security for the surgeon and low permanent morbidity for the patients.

来源:Acta Neurochir (Wien),查看原文。版权归原作者所有。

引用

  1. Leroy HA, Delmaire C, Le Rhun E, et al. High-field intraoperative MRI and glioma surgery: results after the first 100 consecutive patients. Acta Neurochir (Wien). 2019. PMID: 31073784. doi:10.1007/s00701-019-03920-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。